M4 Receptor Allosteric Modulators for Selective CNS Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction, such as schizophrenia, face challenges due to the lack of potent and selective activators of the M4 muscarinic acetylcholine receptor, leading to adverse effects from non-specific activation of peripheral receptors.
Innovation Solution
Development of positive allosteric modulators that selectively activate the M4 muscarinic acetylcholine receptor by binding to an allosteric site distinct from the orthosteric site, reducing peripheral side effects and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AChE inhibitors are used to increase acetylcholine levels, then therapeutic efficacy is improved, but peripheral side effects worsen
Solution Approach 1:
The patent applies local quality by designing a modulator with specific molecular features (aromatic ring systems, heteroatoms, substituent patterns) that confer selective affinity for central M4 receptors over peripheral M2/M3 receptors. This structural differentiation enables the compound to exert therapeutic effects in the CNS while minimizing peripheral cholinergic side effects.
Solution Approach 2:
The patent introduces a selective M4 modulator as an intermediary substance that mediates cholinergic effects specifically at central M4 receptors. This intermediary approach bypasses the non-selective mechanism of AChE inhibitors, allowing therapeutic action in the CNS without direct activation of peripheral muscarinic receptors that cause GI distress and other side effects.
2Reliability
If non-selective mAChR agonists are used to activate muscarinic receptors, then central cholinergic function is improved, but peripheral receptor activation worsens
Solution Approach 1:
The patent employs local quality by incorporating specific structural elements (fused ring systems, heteroatom placement, substituent types) that create high affinity and selectivity for M4 receptors in the central nervous system. This molecular design ensures preferential interaction with central M4 receptors while exhibiting reduced affinity for peripheral M2 and M3 receptors, thereby achieving central efficacy with minimal peripheral activation.
3Reliability
If selective M4 agonists are developed to target central receptors, then therapeutic specificity is improved, but compound selectivity worsens
Solution Approach 1:
The patent applies local quality through precise molecular design featuring aromatic ring systems with specific heteroatoms (nitrogen, oxygen), defined substituent patterns, and particular spatial arrangements that collectively confer high selectivity for M4 receptors. These localized structural features enable the compound to distinguish M4 receptors from other muscarinic subtypes, achieving both therapeutic specificity and compound selectivity.
Data Source
AI summary
Disclosed herein are tricyclic compounds, including 3-(difluoromethyl)-4-methylpyrimido[4′,5′:4,5]thieno[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.